Sodium arsenite inhibited genomic estrogen signaling but induced pERα (Ser118) via MAPK pathway in breast cancer cells

Environmental Toxicology

Volumn 31, Issue 9, 2016, Pages 1133-1146

  Nakareangrit, Watanyoo ^a,b   Thiantanawat, Apinya ^a,b,c   Visitnonthachai, Daranee ^a   Watcharasit, Piyajit ^a,b,c   Satayavivad, Jutamaad ^a,b,c  

^a Chulabhorn Research Institute   (Thailand)

^b Research and Innovation   (Thailand)

^c Thailand Ministry of Science and Technology   (Thailand)

Author keywords

arsenic; breast cancer; ERK1 2; estrogen; pER (Ser118)

Indexed keywords

AMINO ACIDS; ARSENIC; CELLS; CHEMICAL ACTIVATION; CYTOLOGY; DISEASES; GENES; HEALTH RISKS; POTABLE WATER; PROTEINS; SIGNAL TRANSDUCTION; SIGNALING; SODIUM; TRANSCRIPTION;

BREAST CANCER; ENVIRONMENTAL HEALTH; ERK1/2; ESTROGEN; HUMAN BREAST CANCER CELLS; PROLIFERATIVE EFFECTS; SUSTAINED ACTIVATION; TRANSCRIPTIONAL ACTIVITY;

CELL SIGNALING;

ARSENITE SODIUM; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LUCIFERASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; PROGESTERONE RECEPTOR; SERINE;

ARSENIC; ARSENITE; CANCER; CELLS AND CELL COMPONENTS; ENZYME ACTIVITY; ESTROGENIC COMPOUND; GENE EXPRESSION; PROTEIN;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MCF 7 CELL LINE; MDA MB 231 CELL LINE; ONCOGENE C FOS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; T47D CELL LINE; TRANSCRIPTION INITIATION;

EID: 84982104832     PISSN: 15204081     EISSN: 15227278     Source Type: Journal    
DOI: 10.1002/tox.22122     Document Type: Article

References (47)

1. Acconcia F, Kumar R. 2006. Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett 238:1–14.
2. Andrew AS, Mason RA, Memoli V, Duell EJ. 2009. Arsenic activates EGFR pathway signaling in the lung. Toxicol Sci 109:350–357.
3. Barkhem T, Haldosén LA, Gustafsson JA, Nilsson S. 2002. pS2 gene expression in HepG2 cells: complex regulation through crosstalk between the estrogen receptor α, an estrogen-responsive element, and the activator protein 1 response element. Mol Pharmacol 61:1273–1283.
4. Baron S, Escande A, Albérola G, Bystricky K, Balaguer P, Richard-Foy H. 2007. Estrogen receptor α and the activating protein-1 complex cooperate during insulin-like growth factor-I-induced transcriptional activation of the pS2/TFF1 gene. J Biol Chem 282:11732–11741.
5. Callige M, Kieffer I, Richard-Foy H. 2005. CSN5/Jab1 is involved in ligand-dependent degradation of estrogen receptor α by the proteasome. Mol Cell Biol 25:4349–4358.
6. Chambard JC, Lefloch R, Pouyssegur J, Lenormand P. 2007. ERK implication in cell cycle regulation. Biochim Biophys Acta 1773:1299–1310.
7. Chen W, Martindale JL, Holbrook NJ, Liu Y. 1998. Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc. Mol Cell Biol 18:5178–5188.
8. Clemons M, Goss P. 2001. Estrogen and the risk of breast cancer. N Engl J Med 344:276–285.
9. Cooper KL, Liu KJ, Hudson LG. 2007. Contributions of reactive oxygen species and mitogen-activated protein kinase signaling in arsenite-stimulated hemeoxygenase-1 production. Toxicol Appl Pharmacol 218:119–127.
10. Drobna Z, Jaspers I, Thomas DJ, Styblo M. 2003. Differential activation of AP-1 in human bladder epithelial cells by inorganic and methylated arsenicals. FASEB J 17:67–69.
11. Endoh H, Maruyama K, Masuhiro Y, Kobayashi Y, Goto M, Tai H, Yanagisawa J, Metzger D, Hashimoto S, Kato S. 1999. Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor α. Mol Cell Biol 19:5363–5372.
12. Galanis A, Karapetsas A, Sandaltzopoulos R. 2009. Metal-induced carcinogenesis, oxidative stress and hypoxia signalling. Mutat Res 674:31–35.
13. Gao N, Shen L, Zhang Z, Leonard SS, He H, Zhang XG, Shi X, Jiang BH. 2004. Arsenite induces HIF-1α and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. Mol Cell Biochem 255:33–45.
14. Garcia Pedrero JM, Del Rio B, Martinez-Campa C, Muramatsu M, Lazo PS, Ramos S. 2002. Calmodulin is a selective modulator of estrogen receptors. Mol Endocrinol 16:947–960.
15. IARC. 2012. A review of human carcinogens: Arsenic, metals, fibers, and dusts. In: IARC, editor. IARC Monographs on the evaluation of carcinogenic risks to humans. Leon, IARC Press. 100C: p 41–85.
16. Joel PB, Traish AM, Lannigan DA. 1995. Estradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor. Mol Endocrinol 9:1041–1052.
17. Kapaj S, Peterson H, Liber K, Bhattacharya P. 2006. Human health effects from chronic arsenic poisoning—A review. J Environ Sci Health A Tox Hazard Subst Environ Eng 41:2399–2428.
18. Kitchin KT, Wallace K. 2005. Arsenite binding to synthetic peptides based on the Zn finger region and the estrogen binding region of the human estrogen receptor-α. Toxicol Appl Pharmacol 206:66–72.
19. Lannigan DA. 2003. Estrogen receptor phosphorylation. Steroids 68:1–9.
20. Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS. 1994. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 269:4458–4466.
21. Liu Y, Hock JM, Sullivan C, Fang G, Cox AJ, Davis KT, Davis BH, Li X. 2010. Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation. J Cell Biochem 111:1546–1555.
22. Lonard DM, Nawaz Z, Smith CL, O'Malley BW. 2000. The 26S proteasome is required for estrogen receptor-α and coactivator turnover and for efficient estrogen receptor-α transactivation. Mol Cell 5:939–948.
23. Mandal BK, Suzuki KT. 2002. Arsenic round the world: A review. Talanta 58:201–235.
24. Matthews J, Gustafsson JA. 2003. Estrogen signaling: A subtle balance between ERα and ERβ. Mol Interv 3:281–292.
25. Murphy LC, Weitsman GE, Skliris GP, Teh EM, Li L, Peng B, Davie JR, Ung K, Niu YL, Troup S and others. 2006. Potential role of estrogen receptor alpha (ERα) phosphorylated at Serine118 in human breast cancer in vivo. J Steroid Biochem Mol Biol 102:139–146.
26. O'Lone R, Frith MC, Karlsson EK, Hansen U. 2004. Genomic targets of nuclear estrogen receptors. Mol Endocrinol 18:1859–1875.
27. Pianjing P, Thiantanawat A, Rangkadilok N, Watcharasit P, Mahidol C, Satayavivad J. 2011. Estrogenic activities of sesame lignans and their metabolites on human breast cancer cells. J Agric Food Chem 59:212–221.
28. Plotnikov A, Zehorai E, Procaccia S, Seger R. 2011. The MAPK cascades: Signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim Biophys Acta 1813:1619–1633.
29. Prossnitz ER, Maggiolini M. 2009. Mechanisms of estrogen signaling and gene expression via GPR30. Mol Cell Endocrinol 308:32–38.
30. Quinn JA, Graeber CT, Frackelton AR Jr., Kim M, Schwarzbauer JE, Filardo EJ. 2009. Coordinate regulation of estrogen-mediated fibronectin matrix assembly and epidermal growth factor receptor transactivation by the G protein-coupled receptor, GPR30. Mol Endocrinol 23:1052–1064.
31. Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J, Gannon F. 2003. Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11:695–707.
32. Ruiz-Ramos R, Lopez-Carrillo L, Rios-Perez AD, De Vizcaya-Ruiz A, Cebrian ME. 2009. Sodium arsenite induces ROS generation, DNA oxidative damage, HO-1 and c-Myc proteins, NF-κB activation and cell proliferation in human breast cancer MCF-7 cells. Mutat Res 674:109–115.
33. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, Yue W. 2002. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80:239–256.
34. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. 2004. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10(1 Pt 2):331S–336S.
35. Shi H, Shi X, Liu KJ. 2004. Oxidative mechanism of arsenic toxicity and carcinogenesis. Mol Cell Biochem 255:67–78.
36. Simeonova PP, Wang S, Hulderman T, Luster MI. 2002. c-Src-dependent activation of the epidermal growth factor receptor and mitogen-activated protein kinase pathway by arsenic. Role in carcinogenesis. J Biol Chem 277:2945–2950.
37. Stoica A, Pentecost E, Martin MB. 2000. Effects of arsenite on estrogen receptor-α expression and activity in MCF-7 breast cancer cells. Endocrinology 141:3595–3602.
38. Sui M, Jiang D, Hinsch C, Fan W. 2010. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor α to vinblastine and vinorelbine. Breast Cancer Res Treat 121:335–345.
39. Thiantanawat A, Long BJ, Brodie AM. 2003. Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res 63:8037–8050.
40. Thongprakaisang S, Thiantanawat A, Rangkadilok N, Suriyo T, Satayavivad J. 2013. Glyphosate induces human breast cancer cells growth via estrogen receptors. Food Chem Toxicol 59:129–136.
41. Valley CC, Metivier R, Solodin NM, Fowler AM, Mashek MT, Hill L, Alarid ET. 2005. Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor alpha N terminus. Mol Cell Biol 25:5417–5428.
42. Wang C, Mayer JA, Mazumdar A, Fertuck K, Kim H, Brown M, Brown PH. 2011. Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor. Mol Endocrinol 25:1527–1538.
43. Weitsman GE, Li L, Skliris GP, Davie JR, Ung K, Niu Y, Curtis-Snell L, Tomes L, Watson PH, Murphy LC. 2006. Estrogen receptor-α phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression. Cancer Res 66:10162–10170.
44. Wilson VS, Bobseine K, and Gray LE Jr. 2004. Development and characterization of a cell line that stably expresses an estrogen-responsive luciferase reporter for the detection of estrogen receptor agonist and antagonists. Toxicol Sci 81:69–77.
45. Xu Y, Tokar EJ, Waalkes MP. 2014. Arsenic-induced cancer cell phenotype in human breast epithelia is estrogen receptor-independent but involves aromatase activation. Arch Toxicol 88:263–274.
46. Zhang D, Trudeau VL. 2006. Integration of membrane and nuclear estrogen receptor signaling. Comp Biochem Physiol A Mol Integr Physiol 144:306–315.
47. Zhang W, Wang L, Fan Q, Wu X, Wang F, Wang R, Ma Z, Yang J, Lu SH. 2011. Arsenic trioxide re-sensitizes ERα-negative breast cancer cells to endocrine therapy by restoring ERα expression in vitro and in vivo. Oncol Rep 26:621–628.